LGALS3 and hepatocellular carcinoma: In the current research, the LGALS3 and HCP5 expression levels were significantly positively associated with multiple immune checkpoints, which provided potential targets for immunotherapy and indicated a better response to the immune-inhibiting treatments in HCC patients with high LGALS3 and HCP5 expression.